These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19527192)

  • 21. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Dauner DG; Nelson RE; Taketa DC
    Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
    Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
    Chambers HF
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():17-22. PubMed ID: 16524424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftobiprole medocaril: a new generation beta-lactam.
    Del Pozo JL; Patel R
    Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftaroline fosamil: drug profile and clinical data.
    Kanafani ZA
    Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
    Garrison MW; Kawamura NM; Wen MM
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftobiprole - a case study.
    Page MG
    Expert Opin Drug Discov; 2007 Jan; 2(1):115-29. PubMed ID: 23496040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
    Pfaller MA; Flamm RK; Duncan LR; Shortridge D; Smart JI; Hamed KA; Mendes RE; Sader HS
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):304-313. PubMed ID: 30808530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
    Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
    J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.